RedHill Biopharma Ltd – (RDHL) Reaches New 1-Year High at $16.54
RedHill Biopharma Ltd – (NASDAQ:RDHL) reached a new 52-week high during trading on Thursday . The company traded as high as $16.54 and last traded at $16.20, with a volume of 113,514 shares changing hands. The stock had previously closed at $15.31.
A number of equities research analysts have commented on RDHL shares. Zacks Investment Research cut RedHill Biopharma Ltd – from a “hold” rating to a “sell” rating in a report on Friday, July 29th. FBR & Co raised their price target on RedHill Biopharma Ltd – from $33.00 to $36.00 and gave the company an “outperform” rating in a report on Wednesday, July 27th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $26.00.
The stock has a 50 day moving average of $11.58 and a 200 day moving average of $11.19. The stock’s market cap is $207.44 million.
RedHill Biopharma Ltd – (NASDAQ:RDHL) last released its earnings results on Wednesday, July 27th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.52. Equities analysts anticipate that RedHill Biopharma Ltd – will post ($1.97) EPS for the current fiscal year.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.